DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Coral Laboratories Ltd (CORALAB) share price today?

Coral Laboratories Ltd (CORALAB) is trading at ₹588 on the BSE, down 2.01% on the day. Source: DocStoX.

What is the PE ratio of Coral Laboratories Ltd?

Coral Laboratories Ltd has a price-to-earnings (PE) ratio of 8.7 in the Healthcare sector.

What is the market capitalisation of Coral Laboratories Ltd?

Coral Laboratories Ltd has a market capitalisation of approximately ₹214 crore.

Coral Laboratories Ltd

CORALAB·BSE·Healthcare

₹588.00▼ -12.05 (-2.01%)

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

Day₹588.00

₹598.00

52W₹360

₹65976%

Open

₹598.00

High

₹598.00

Low

₹588.00

Prev Close

₹600.05

Volume

285

VWAP

₹589.98

Snapshot

Key fundamentals

Market Cap

₹214 Cr

P/E Ratio

8.69Cheap

P/B Ratio

1.02

EPS

₹67.63

Book Value

₹585.74

ROE

12.01%Average

ROCE

17.00%Decent

Dividend Yield

0.25%

Debt / Equity

0.02Low

Face Value

₹10.00

52W High

₹659.00

52W Low

₹360.00

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Fairly Valued

None moatMedium uncertainty

Fair value estimate

₹628

▲ 6.9%upside

Trading at ₹588 — 7% below our estimate

BearFair valueBull

₹534₹628₹767

/100

Business quality — Solid

Growth 50Profitability 68Efficiency 45Valuation 100

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet

Strengths

Virtually debt-free balance sheet
Reasonably priced at 9× earnings
Promoters hold a controlling stake

How we got there

Fair value methods

Residual income

12% ROE fading to 12% over ~3 yrs, on ₹586 book

₹590

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹767

Analyst target

No analyst coverage

—

Blended fair value₹628

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Reasonably priced at 9× earnings
Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

8.7Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

12.0%Average

Above 15% is considered healthy for Indian equities

ROCE

17.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.02Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹214 Cr

P/B

1.02

EPS

₹67.63

Div Yield

0.25%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Attractive

P/E 8.7×

Growth

Slow

+3% rev CAGR

Profitability

Healthy

12.0% ROE

Financial health

Rock solid

D/E 0.02

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹1.68L Cr

Trades11

VWAP₹589.98

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+3.3%

-2.4%

10Y

+1.1%

Profit

+42.4%

+4.4%

10Y

+3.7%

EPS

+35.2%

+3.3%

10Y

+2.5%

Profile

Pros

Company is almost debt free.
Stock is trading at 1.03 times its book value

Watch-outs

Cons

The company has delivered a poor sales growth of -2.31% over past five years.
Company has a low return on equity of 10.1% over last 3 years.
Earnings include an other income of Rs.10.2 Cr.
Working capital days have increased from 217 days to 328 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

72%

Promoter

Promoters

71.5%0.00

Public

19.9%0.00

FII / FPI

0.0%0.00

DII

0.0%0.00

Others

8.6%

Total shareholders

3,873-211 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter71.51%

Public19.93%

Others8.56%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1994, Coral Laboratories Ltd is in the business of pharmaceutical formulations[1]